Search results for "Typing"

showing 10 items of 1051 documents

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual…

2015

Background Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells (PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and predictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we verified if these markers could be associated with disease stage/response to therapy despite the role of clinical parameters. Results: significant changes in the expression of markers…

OncologyCD20Prognostic variablemedicine.medical_specialtyPathologyHistologybiologybusiness.industryCD58Cell BiologyPlasma cellmedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureImmunophenotypingInternal medicinemedicinebiology.proteinStage (cooking)businessCytometryMultiple myelomaCytometry Part B: Clinical Cytometry
researchProduct

Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor…

2018

9101Background: Approximately 20 % of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. In this study, we have anal...

OncologyCancer Researchmedicine.medical_specialtyLungbusiness.industryDNA sequencingSubtypingInsufficient Tissuemedicine.anatomical_structureOncologyInternal medicineMedicineIn patientStage (cooking)businessGenotypingJournal of Clinical Oncology
researchProduct

FcγRIIa and Fc γ RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

2014

Abstract Purpose: FcγR polymorphisms have been reported to enhance the immune-mediated effects of cetuximab in metastatic colorectal cancer. There are no data on the relationship between these polymorphisms and cetuximab in the early-stage setting. We performed a pharmacogenomic analysis of EXPERT-C, a randomized phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery, and adjuvant CAPOX ± cetuximab in high-risk, locally advanced rectal cancer. Experimental Design: FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms were analyzed on DNA from peripheral blood samples. Kaplan–Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment…

OncologyCancer Researchmedicine.medical_specialtyPrognostic variableGenotypeColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicineGenotypemedicineHumansGenotypingCetuximabProportional hazards modelbusiness.industryReceptors IgGPrognosismedicine.diseaseErbB ReceptorsTreatment OutcomeOncologyImmunologyColorectal NeoplasmsbusinessAdjuvantChemoradiotherapymedicine.drugClinical Cancer Research
researchProduct

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

2014

Background Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide polymorphisms (SNPs) may help explain the heterogeneity of neuroblastoma and assist in identifying patients at higher risk for poor survival. SNPs in the TP53 pathway are of special importance, as several studies have reported associations between TP53 pathway SNPs and cancer. Of note, less than 2% of neuroblastoma tumors have a TP53 mutation at diagnosis. Patients and Methods We selected 21 of the most frequently studied SNPs in the TP53 pathway and evaluated their assoc…

OncologyGenotyping TechniquesMedizinlcsh:MedicineGenome-wide association studyPROGRESSIONSUSCEPTIBILITYBioinformaticsNeuroblastomaCHEMOSENSITIVITYMedicine and Health SciencesMissense mutationlcsh:ScienceOncogene ProteinsCaspase 8N-Myc Proto-Oncogene ProteinMultidisciplinaryCELL-LINENuclear ProteinsCANCERAPOPTOSISGENOTYPEGene Expression Regulation NeoplasticResearch Articlemedicine.medical_specialtySingle-nucleotide polymorphismBiologyN-Myc Proto-Oncogene ProteinPolymorphism Single NucleotideDisease-Free SurvivalMDM2 SNP309Molecular GeneticsNeuroblastomaInternal medicineCASPASE-8medicineGeneticsCancer GeneticsSNPHumansneoplasmsNeoplasm StagingClinical GeneticsP53lcsh:RGene AmplificationCancerInfantBiology and Life Sciencesmedicine.diseasePediatric cancerGeriatricsGenetics of Diseaselcsh:Q
researchProduct

Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensu…

2012

Abstract Background Recent emerging evidences identify Human Papillomavirus (HPV) related Head and Neck squamous cell carcinomas (HN-SCCs) as a separate subgroup among Head and Neck Cancers with different epidemiology, histopathological characteristics, therapeutic response to chemo-radiation treatment and clinical outcome. However, there is not a worldwide consensus on the methods to be used in clinical practice. The endpoint of this study was to demonstrate the reliability of a triple method which combines evaluation of: 1. p16 protein expression by immunohistochemistry (p16-IHC); 2. HPV-DNA genotyping by consensus HPV-DNA PCR methods (Consensus PCR); and 3 viral integration into the host…

OncologyHuman papillomavirusHPVCancer Researchmedicine.medical_specialtyPathologyMethylation-Specific PCREpidemiologySettore MED/50 - Scienze Tecniche Mediche ApplicateBisulfite sequencingConsensus PCRIn situ hybridizationSettore MED/08 - Anatomia Patologicalcsh:RC254-282lcsh:Infectious and parasitic diseasesHPV-DNA; in situ hybridationSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineDNA consensus PCRlcsh:RC109-216p16-IHCin situ hybridationGenotypingHN-SCCOPSCCbusiness.industryHead and neck cancerEpigeneticHPV-DNAHead and neck squamous cell carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryHead and neck squamous-cell carcinomastomatognathic diseasesInfectious DiseasesReal-time polymerase chain reactionOncologyImmunohistochemistryOSCCbusinessResearch ArticleIHCInfectious Agents and Cancer
researchProduct

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

2010

Summary Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and informa…

OncologyInternational CooperationUterine Cervical NeoplasmsPolymerase Chain ReactionHuman papillomaviruses ; cervical cancer0302 clinical medicineGenotypeMass ScreeningYoung adult10. No inequalityPapillomaviridaeCervical cancerAged 80 and over0303 health sciencesParaffin Embeddingmedicine.diagnostic_testAge FactorsMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentGenotypeHPV vaccinesAdenocarcinoma03 medical and health sciencesCarcinoma AdenosquamousYoung AdultInternal medicinemedicineHumansNeoplasm InvasivenessGenetic TestingPapillomavirus VaccinesGenotyping030304 developmental biologyGenetic testingAgedRetrospective StudiesGynecologybusiness.industryPapillomavirus InfectionsBasic Medical Sciencesmedicine.diseaseCross-Sectional StudiesLogistic ModelsBIOMEDICINE AND HEALTHCAREDNA ViralLinear Array HPV Genotyping TestLinear ModelsCervarixbusinessThe Lancet. Oncology
researchProduct

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

2015

OBJECTIVE: We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large cohort with sufficient statistical power was assembled.DESIGN: To show a HR advantage of 0.6 in progression-free survival (PFS) for FCGR2A-HH versus the rest and FCGR3A-VV versus the rest, with an 80% power, 80 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type (KRAS-WT) and 52 KRAS-WT patients are required, respectively. This leads to a total sample size of 952 and 619 patients, respectively. Samples were collected from 1123 mCRC patients from 15 European centres treated wit…

OncologyMaleReceptors IgG/geneticsGenotyping TechniquesColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeGenetic PolymorphismsErbB Receptors/antagonists & inhibitorsNeoplasm MetastasisAntibody Targeted TherapyImmune ResponseAged 80 and overbiologyCetuximabGastroenterologyColorectal Neoplasms/drug therapyMiddle AgedErbB ReceptorsSurvival RateAntibodies Monoclonal Humanized/therapeutic useFemaleKRASAntibodyColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsAntibodies Monoclonal HumanizedDisease-Free SurvivalYoung AdultRefractoryInternal medicinemedicineHumansneoplasmsGerm-Line MutationAgedColorectal CancerChemotherapyPolymorphism Geneticbusiness.industryReceptors IgGAntineoplastic Agents/therapeutic usemedicine.diseasedigestive system diseasesOxaliplatinIrinotecanImmunologybiology.proteinbusinessGenotyping Techniques/standards
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct

Comparison of genetic risk prediction models to improve prediction of coronary heart disease in two large cohorts of the MONICA/KORA study

2021

Abstract It is still unclear how genetic information, provided as single‐nucleotide polymorphisms (SNPs), can be most effectively integrated into risk prediction models for coronary heart disease (CHD) to add significant predictive value beyond clinical risk models. For the present study, a population‐based case‐cohort was used as a trainingset (451 incident cases, 1488 noncases) and an independent cohort as testset (160 incident cases, 2749 noncases). The following strategies to quantify genetic information were compared: A weighted genetic risk score including Metabochip SNPs associated with CHD in the literature (GRSMetabo); selection of the most predictive SNPs among these literature‐co…

Oncologymedicine.medical_specialtyEpidemiologyFramingham Risk Score ; Metabochip ; Coronary Heart Disease ; Genomic Risk Prediction ; Priority-lassoPopulationCoronary DiseaseSingle-nucleotide polymorphismKoronare HerzkrankheitPolymorphism Single NucleotideRisk AssessmentCohort Studies03 medical and health sciencesRisk FactorsInternal medicinemedicineHumansgenomic risk predictionddc:610coronary heart diseaseMetabochipGenetikeducationGenotypingGenetics (clinical)030304 developmental biologypriority‐Lasso0303 health scienceseducation.field_of_studyFramingham Risk ScoreModels GeneticProportional hazards modelbusiness.industry030305 genetics & heredityGenomicsConfidence intervalddc:Coronary disease; GeneticsRisk factorsCohortFramingham risk scorebusinessDDC 610 / Medicine & healthPredictive modelling
researchProduct

Revisiting the metallothionein genes polymorphisms and the risk of oral squamous cell carcinoma in a Brazilian population

2020

Background Metallothioneins (MTs) gene polymorphisms have been associated with the ability of free radical scavenging and detoxification of heavy metals leading to cancer development. Our aim was to revisit, in a Brazilian population, single-nucleotide polymorphisms (SNPs) of the MT gene family previously associated with oral squamous cell carcinoma (OSCC). Material and Methods A case-control investigation with 28 OSCC patients and 45 controls was conducted, using conventional risk factors (tobacco use and alcohol consumption) as covariates. SNPs genotyping for rs8052334 (MT1B), rs964372 (MT1B), and rs1610216 (MT2A) was performed by PCR-RFLP, and SNPs for rs11076161 (MT1A) were analyzed by …

Oncologymedicine.medical_specialtyLinkage disequilibriumGenotypePopulationSingle-nucleotide polymorphismBiologygallium aluminium arsenide lasersPolymorphism Single NucleotideRisk FactorsOral Cancer and Potentially malignant disordersInternal medicineGenotypemedicineHumansSNPGenetic Predisposition to Diseasethird molareducationGeneral DentistryGenotypingUNESCO:CIENCIAS MÉDICASeducation.field_of_studycontrolled clinical trialSquamous Cell Carcinoma of Head and NeckResearchHaplotypestomatognathic diseasesOtorhinolaryngologyHead and Neck NeoplasmsCase-Control StudiesCarcinoma Squamous CellMetallothioneinMouth NeoplasmsSurgeryGene polymorphismBrazilMedicina Oral Patología Oral y Cirugia Bucal
researchProduct